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Human immunodeficiency virus type 1 (HIV-1) is restricted for replication in rhesus macaque cells and does not establish
infection in this species. The block to productive infection of macaque peripheral blood mononuclear cells (PBMC) in culture
was investigated. A chimeric virus SHIV containing HIV-1 tat, rev, and env and all other genes from a simian immunodeficiency
virus clone pathogenic in macaques (i.e., SIVmac239) replicated efficiently in macaque PBMC. Thus, the attachment step,
involving interaction of the HIV-1 env glycoprotein with the cell surface CD4 receptor, is not blocked. Analysis of uptake of
HIV-1 particles in these cells revealed a small reduction in virion entry; however, viral DNA synthesis, measured by PCR
amplification, was greatly reduced. Taken together, these results indicate that the block to HIV-1 (subtype B) replication in
rhesus macaque cells involves release of the virion core into the cytoplasm and/or a step immediately prior to initiation of
reverse transcription. Further studies are required to characterize this block through identification of species-specific cellular
proteins that interact with HIV-1 proteins in the early phase of viral replication. q 1996 Academic Press, Inc.
HIV-1 and HIV-2 (human immunodeficiency virus type caque virus, designated SIVmac, causes a fatal AIDS-
like disease in several macaque species. Although SIV1 and type 2) are T-lymphocytopathic viruses that infect
humans and cause AIDS. Although HIV-1 has been re- shows several biological similarities to HIV-1, genetic
differences limit the use of SIV infection of susceptibleported to produce a low-level infection in nemestrina
macaques without inducing disease (1), this virus cannot macaques for testing anti-HIV-1 vaccines and drugs
and analyzing roles of HIV-1 genes in chronic infectionestablish infection in rhesus macaques (2). This in vivo
observation is reflected in the finding that HIV-1 repli- and pathogenesis.
To study the restriction of HIV-1 infection in nonhumancates poorly in primary rhesus macaque lymphocyte cul-
tures (3). The restriction of HIV-1 replication in simian primates, we prepared peripheral blood mononuclear cells
(PBMC) from two rhesus macaques (Macaca mulatta) andcells is somewhat surprising because T-lymphocytes of
New and Old World monkeys express a surface antigen tested these cells for supporting replication of HIV-1SF33, a
T-cell line tropic, cytopathic virus (9). Previous studies dem-that exhibits high sequence homology to human CD4 (4).
Species tropism has not been extensively studied for onstrated that SHIVSF33, a chimeric virus containing HIV-1
tat, rev, and env and all other genes from the pathogenicprimate lentiviruses. This becomes an important issue
for utilizing nonhuman primates for studying mechanisms molecular clone SIVmac239 (10), replicated in PBMC from most
but not all rhesus macaques (C. Cheng-Mayer and P. Luciw,of HIV-1 pathogenesis and for development of anti-HIV-
1 vaccines and therapies. unpublished results). SHIVSF33 establishes persistent infec-
tion in rhesus macaques (11) and has recently been associ-SIV (simian immunodeficiency virus) is a group of
distinct lentiviruses isolated from several African mon- ated with immunosuppression in these animals (P. Luciw
and C. Cheng-Mayer, unpublished results). Accordingly, thiskey species (e.g., African green monkey, sooty manga-
bey, mandrill, sykes). These viruses produce chronic virus was included in this study to test whether or not PBMC
from rhesus macaques are permissive for the SHIV con-infection but no disease in their natural host (5). How-
ever, SIV from sooty mangabey (6) and African green taining the HIV-1SF33 env as well as tat and rev. Growth
kinetics of HIV-1SF33, SIVmac239, and SHIVSF33env were com-monkey (7) causes an AIDS-like disease and death in
experimentally inoculated Asian macaques. A small pared in macaque and human PBMC cultures; levels of
virion associated core protein were measured in samplesnumber of macaques held captive in primate facilities
have been shown to be infected with a lentivirus highly of culture media collected over a period of 9 days. SHIVSF33env
and SIVmac239 replicated efficiently in PBMC of both ma-related to SIV from sooty mangabeys (5, 8). The ma-
caques and produced cytopathic effects, whereas HIV-1SF33
replication was reduced greater than 100-fold relative to ei-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (916) 752-4548. ther of these two viruses (Fig. 1). All of the viruses in this
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amount of p24gag from infected macaque-1 and macaque-
2 PBMC was about 45 and 10% of the amount in human
PBMC, respectively; these results demonstrate a 2- to
10-fold reduction of HIV-1 entry into macaque PBMC
compared to human PBMC.
To further analyze the step(s) at which HIV-1 replica-
tion is blocked in macaque PBMC, levels of viral DNA
were measured by a semiquantitative PCR assay in cell
cultures at 1 and 2 days after infection with HIV-1SF33 .
Initiation of reverse transcription was assessed by mea-
suring the amount of the 140-bp PCR product which rep-
resents strong-stop minus-strand viral DNA (Fig. 3A). The
small amount of 140-bp HIV-1 DNA detected in macaque
PBMC (Fig. 3B) could be due to initiation of viral DNA
synthesis in virions prior to exposure of cells to virus;
newly initiated viral DNA has been reported in mature
retrovirus particles (12, 13). Accordingly, we performed
an analysis of viral DNA synthesis in cultures treated
with the reverse transcription inhibitor azidothymidine
(AZT). No significant difference was observed in the
amount of 140-bp HIV-1 DNA in untreated and AZT-
treated macaque PBMC exposed to HIV-1SF33 (Fig. 3C);
thus, the 140-bp band shown in Fig. 3B, in macaque cells,
FIG. 1. Viral replication of HIV-1SF33 , SIVmac239 , and SHIV viruses
in human and rhesus macaque PBMC. Culture medium for PBMC
was RPMI 1640 supplemented with 10% fetal bovine serum, 100
units/ml penicillin, 100 mg/ml streptomycin, and 1 mM L-glutamine.
Human PBMC from a healthy, HIV seronegative donor were pre-
pared by Ficoll – Hypaque density centrifugation of heparinized
blood and stimulated with 5 mg/ml of phytohemagglutinin for 3 days.
PBMC from two rhesus macaques (macaque-1 and macaque-2)
were also prepared by the same procedure except these cells were
stimulated with 0.5 mg/ml of Staphylococcus enterotoxin A (Toxin
Technology, Inc., Sarasota, FL). After the 3-day stimulation period,
cultures of (A) human and (B and C) macaque PBMC were inocu-
lated with HIV-1SF33 , SIVmac239 , and SHIVSF33env at a multiplicity of
infection (m.o.i.) of 0.01 TCID50 per cell and maintained in culture
medium supplemented with 100 units per milliliter of human recom-
binant interleukin-2 (AIDS Research and Reference Reagent Pro-
gram, NIH). Culture supernatants were collected at 0, 3, 5, 7, and 9
days after infection and analyzed for virus production by measuring
reverse transcriptase activity (26). Virus inocula were prepared by
transfecting CEMX174 cells and tested for infectivity by end-point
titration on CEMX174 cells to determine the 50% tissue culture infec-
tious dose (TCID50). FIG. 2. Viral entry assay for HIV-1SF33 . Stimulated PBMC from a hu-
man donor, macaque-1, and macaque-2 were incubated in triplicate
with HIV-1SF33 for 2 hr at 377. Each culture contained 4 1 105 cells per
study replicated and caused cytopathology in human PBMC 1 ml. The amount of inoculated virus for each cell culture is 1 pg per
cell as determined by measuring p24gag protein by antigen capture(Fig. 1).
ELISA (Coulter, Hialeah, FL). After this initial incubation, cells wereTo investigate the block at the early phase of viral
washed three times with PBS and treated with 0.25% trypsin for 5 minreplication, uptake of HIV-1SF33 was examined in ma- at room temperature to eliminate adherent but noninternalized viral
caque and human PBMC. A sensitive ELISA was used particles absorbed to the cell surface. Cells were then washed once
to measure the amount of viral core antigen which is with 5% fetal bovine serum in PBS. Cell pellets were collected by low-
speed centrifugation and lysed in buffer containing 0.5% Triton X-100internalized in cells exposed to intact virions. Nonspecific
and 100 mM Tris, pH 7.5. The amount of p24gag in cell lysates wasadsorption of virus was measured in PBMC cultures incu-
measured by antigen-capture ELISA (Coulter, Hialeah, FL) to determinebated with heat-inactivated virus, and trypsin was used
internalization of viral particles. Human and macaque PBMC incubated
to remove virions that were not internalized. As shown with heat-inactivated HIV-1SF33 served as controls. Results are the
in Fig. 2, the viral core antigen p24gag was readily de- means { standard error of triplicate samples. This assay is modified
from the method described by Harouse et al. (27).tected in PBMC cultures from both macaques. The
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probably represents viral DNA in the inoculum and not
newly initiated viral DNA produced in the course of infec-
tion of macaque PBMC. The 200-bp PCR product, repre-
senting complete or nearly complete proviral DNA (Fig.
3A), was barely detectable in macaque cells exposed to
HIV-1SF33 (Fig. 3B). These results indicate that the block
to HIV-1 replication in rhesus macaque PBMC is at the
early phase of viral replication, involving a step(s) prior
to initiation of reverse transcription.
Steps in the early phase of retrovirus replication in-
clude binding of virions to the cell surface receptor, fu-
sion of virion and cell membranes, release of the viral
ribonucleoprotein core into the cytoplasm (uncoating),
reverse transcription in the cytoplasm to produce double-
stranded viral DNA, transport of the viral nucleoprotein
complex into the nucleus, and integration of linear viral
DNA into the host cell genome (14). The chimeric virus
SHIVSF33 , expressing HIV-1 glycoprotein, entered and
replicated in rhesus macaque PBMC (Fig. 1); this result
indicates that restriction of HIV-1 replication is not at the
level of viral binding to the CD4 receptor. To focus on
entry of HIV-1 into cells, we examined internalization of
viral particles in an assay that measured the amount of
viral core antigen (i.e., p24gag) taken up by PBMC in cul-
ture; this experiment revealed that HIV-1 entry was re-
duced 2- to 10-fold in macaque cells. Measurements of
viral DNA in PBMC exposed to HIV-1 showed a very
small amount of strong-stop minus-strand DNA in HIV-
1SF33-infected rhesus macaque PBMC compared to hu-FIG. 3. PCR analysis of HIV DNA in human and rhesus macaque
man PBMC (Fig. 3B). Control experiments with the re-PBMC. (A) The PCR primer pair specific for the R/U5 region of the HIV-1
LTR, M667 and AA55, was used to detect the early reverse transcription verse transcriptase inhibitor AZT demonstrated that this
product (140 bp). The second primer pair specific for the LTR/gag HIV-1 DNA in macaque cells was not newly initiated
region, M667 and M661, detects a late reverse transcription product after entry but most likely was present in virions in the
(200 bp). Sequences for these primers are in the publication by Zack
inoculum. Thus, our study demonstrates that the restric-et al. (28). (B) Stimulated human and rhesus macaque PBMC (macaque-
tion of HIV-1 replication in rhesus macaque PBMC is at1, Fig. 1) were exposed to HIV-1SF33 at a m.o.i. of 0.2 TCID50 per cell
and incubated at 377 for 1 hr. After adsorption, cells were washed three an early step(s), after virion binding to the CD4 cell sur-
times and maintained in culture medium supplemented with recombi- face receptor but prior to reverse transcription. Shibata et
nant IL-2. Cell samples were collected at 24 and 48 hr after infection al. (15) also reported that HIV-1 is blocked in cynomolgus
and cell pellets were lysed in buffer containing 10 mM Tris, pH 8.3,
macaque cells at an early step in viral replication.0.45% NP-40, 0.45% Tween-20, and 100 mg proteinase K. To estimate
The mechanism of entry of HIV and SIV particles intoviral DNA copy number, a standard curve was generated by analysis
of DNA from the 8E5/LAV cell line which contains one copy of integrated cells is not well understood. Following attachment of
HIV-1 DNA per cell; this cell line was obtained from the AIDS Research virions via binding of the surface subunit (gp120) of the
and Reference Reagent Program, NIH (29). To control for the amount env glycoprotein to the CD4 receptor, viral and cell mem-
of infected cell DNA substrate for PCR amplification, a primer pair
branes fuse and the ribonucleoprotein core of the virionspecific for the human b-globin gene, PC03 and PC04, was included
is released into the cytoplasm (14). This core is inferredin all reactions (30). For detection of PCR amplification products, one
primer from each pair of primers was end-labeled with [32P]ATP by T4- to contain capsid proteins as well as reverse tran-
polynucleotide kinase. Buffer for PCR amplification containing 1.5 mM scriptase, integrase, and the dimeric form of the viral RNA
MgCl2 , 50 mM KCl, 100 mM Tris, pH. 8.3, was mixed to 0.2 mM dNTP genome with the tRNA primer hydrogen-bonded near the
per nucleotide, 2 units of Taq polymerase (Perkin–Elmer Cetus, U.S.A.),
5* end. Our results suggest that a species-specific celland 20 pmol of the appropriate primers in a total volume of 50 ml. The
protein(s) plays a role either in release of the viral corePCR mixtures were subjected to 2 cycles of amplification by thermal
cycler (Perkin–Elmer Cetus) at 947 for 3 min, 657 for 3 min, and to 30 into the cytoplasm or at a step immediately prior to initia-
cycles of 947 for 1 min, 657 for 2 min. After the PCR amplification, DNA tion of viral DNA synthesis by reverse transcriptase. Ac-
products were analyzed by electrophoresis on polyacrylamide gels and cordingly, we hypothesize that macaque cells either do
visualized by autoradiography of dried gels. (C) Rhesus macaque PBMC
not possess this protein or express a form different fromwere infected in the absence or presence of 5 mM AZT, and the levels
that in human cells. A cellular immunophillin protein(s)of newly initiated viral DNA (i.e., 140 bp DNA detected with primers
M667 and AA55) were measured at 0, 6, and 12 hr postinfection. has been shown to be required for HIV-1 replication (16–
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